Literature DB >> 2246554

Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting.

J Singh1, A W Dudley, K A Kulig.   

Abstract

Serum samples from 398 individuals (270 whites and 128 blacks) exhibiting quantitatively normal amounts of five typically seen fractions (albumin, alpha 1-globulin, alpha 2-globulin, beta-globulin, and gamma-globulin) in serum protein electrophoresis and showing no evidence of multiple myeloma, other immunoproliferative diseases, or any of the other diseases known to produce monoclonal proteins were tested for monoclonal gammopathy of undetermined significance (MGUS) by immunofixation electrophoresis. No individual in the study had a serum protein electrophoresis pattern suggestive of monoclonal protein gammopathy. Except for one 37-year-old woman, all subjects were men. Subjects were divided into seven age groups: 20 to 29 years (I), 30 to 39 years (II), 40 to 49 years (III), 50 to 59 years (IV), 60 to 69 years (V), 70 to 79 years (VI), and all over 79 years (VII) of age. Considering all subjects in a given race, blacks had two times (14.8%) higher incidence of MGUS than whites (7.8%); this difference was statistically significant. An increased incidence of MGUS in blacks when compared with whites prevailed in each age group, and the difference was statistically significant in all age groups except group II. No MGUS was found in groups I and III in either race. Both races showed a threefold increase in incidence of MGUS from group II to group VII. No routine laboratory test such as erythrocyte sedimentation rate in subjects with MGUS was significantly different than that in age- and race-matched individuals without MGUS. These results show that the incidence of MGUS is higher in the group (blacks) also known to have a higher prevalence of multiple myeloma.

Entities:  

Mesh:

Year:  1990        PMID: 2246554

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  10 in total

1.  Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.

Authors:  Ola Landgren; S Vincent Rajkumar; Ruth M Pfeiffer; Robert A Kyle; Jerry A Katzmann; Angela Dispenzieri; Qiuyin Cai; Lynn R Goldin; Neil E Caporaso; Joseph F Fraumeni; William J Blot; Lisa B Signorello
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

2.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

Authors:  Ola Landgren; Gloria Gridley; Ingemar Turesson; Neil E Caporaso; Lynn R Goldin; Dalsu Baris; Thomas R Fears; Robert N Hoover; Martha S Linet
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

3.  The significance of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Shaji Kumar
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

Review 4.  Prevalence, clinical aspects, and natural history of IgM MGUS.

Authors:  Mary L McMaster; Ola Landgren
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

Review 5.  Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.

Authors:  A J Greenberg; C M Vachon; S V Rajkumar
Journal:  Leukemia       Date:  2011-12-23       Impact factor: 11.528

Review 6.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

7.  Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.

Authors:  Parameswaran N Hari; Navneet S Majhail; Mei-Jie Zhang; Anna Hassebroek; Fareeha Siddiqui; Karen Ballen; Asad Bashey; Jenny Bird; Cesar O Freytes; John Gibson; Gregaory Hale; Leona Holmberg; Ram Kamble; Robert A Kyle; Hillard M Lazarus; Charles F LeMaistre; Fausto Loberiza; Angelo Maiolino; Philip L McCarthy; Gustavo Milone; Nancy Omondi; Donna E Reece; Matthew Seftel; Michael Trigg; David Vesole; Brendan Weiss; Peter Wiernik; Stephanie J Lee; J Douglas Rizzo; Paulette Mehta
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-14       Impact factor: 5.742

8.  Understanding the multiple biological aspects leading to myeloma.

Authors:  Eileen M Boyle; Faith E Davies; Xavier Leleu; Gareth J Morgan
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

9.  Prevalence and type of monoclonal gammopathy of undetermined significance in an apparently healthy Nigerian population: a cross sectional study.

Authors:  A Lawretta Onwah; Titilope A Adeyemo; Adewumi Adediran; Sarah O Ajibola; Alani S Akanmu
Journal:  BMC Blood Disord       Date:  2012-06-28

10.  Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study.

Authors:  Ling Ma; Shuang Xu; Jianhua Qu; Jian Hou; Yang Wang; Lei Wen; Yang Liu; Ying Kang; Ming Jiang; Weijun Fu; Juan Du; Lin Zhou; Xiaojun Huang; Zhaoxia Zhang; Jin Lu
Journal:  Hematol Oncol       Date:  2018-10-01       Impact factor: 5.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.